1. DEVELOPMENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS: FOCUS ON SMALL MOLECULES

2. Introduction/Background

3. RA Is a Heterogeneous Complex Syndrome[a-d]

4. RA: Clinical Description and Sequelae

5. The Fate of Untreated RA

6. Immune and Inflammatory Responses: Pathogenesis of Synovitis Characteristic of RA

7. IL-6 in Inflammation, Immunity, and Disease

8. IL-6 and RA Pathogenesis

9. Many Cytokines and Growth Factors Converge on the JAK Signaling Pathway[a-c]

10. JAK-STAT Signaling in RA[a-c]

11. Focus on the JAK-STAT Pathway: Physiologic Roles

12. JAK-STAT Signaling and the Immune Response

13. The Biological Significance of Signaling Through Different JAK Combinations

14. The Human Canonical Model of JAK-STAT Signaling

15. Dysregulated JAK-STAT Signaling and RA Pathogenesis

16. Elevated STAT3 Expression in Patients With Early RA

17. The JAK-STAT Pathway and RA Pharmacotherapeutics

18. Tofacitinib JAK 1/3 Inhibitor: Clinical Trials in RA

19. Tofacitinib or ADA vs PBO in RA: Results From ORAL Standard

20. Tofacitinib JAK 1/3 Inhibitor: Clinical Trial Results From ORAL Start

21. Proportion of TNF-IR, DMARD-IR, and MTX-Naive Patients With ACR50 Response in Tofacitinib Trials

22. Baricitinib: Key Studies in RA Phase 3 Program and Their Characteristics

23. Baricitinib JAK 1/2 Inhibitor: RA-BEAM Results Overview

24. RA-BEAM Phase 3: ACR Outcomes at Weeks 12 and 24

25. PROs: RA-BEAM Phase 3 Trial of Baricitinib

26. Baricitinib JAK 1/2 Inhibitor: RA-BUILD Results Overview

27. RA-BUILD Phase 3: PROs at Week 24 Baricitinib in csDMARD-IR and bDMARD-Naive Patients With Moderate to Severe RA

28. RA-BEACON: Baricitinib in RA Patients With an Inadequate Response to TNF-ɑ Inhibitors

29. Results From the Baricitinib LTE RA-BEYOND Trial

30. Filgotinib JAK 1 Inhibitor: Clinical Trial Results in RA

31. DARWIN 1 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib + MTX in Patients With Active RA

32. DARWIN 2 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib Monotherapy in Patients With Active RA

33. RA Pharmacotherapeutics: Other Targets and Agents

34. Summary and Conclusions

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)

38. Abbreviations (cont)